Skip to main content

Advertisement

SpringerLink
Log in

The role of ABCB1 polymorphism as a prognostic marker for primary central nervous system lymphoma

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

To investigate the possible role of functional single nucleotide polymorphism (SNP) in circadian genes as prognostic markers of primary central nervous system lymphoma (PCNSL). We conducted a prospective study using data from Huashan Hospital 2006–2015 and followed up 91 PCNSL patients until June 30, 2016. The survival of patients with different prognostic factors was compared by log-rank test. Univariate and multivariate analyses were performed by Cox regression. During a long-term follow-up (6–110 months), overall survival (OS) was 32 months (95% CI, 13.3–91.1) and progression-free survival (PFS) was 23 months (95% CI, 9.0–41.0) for the entire cohort. Age (P = 0.046, P = 0.001) and performance status (PS) score (P = 0.013, P = 0.003) showed differences in OS and PFS. ABCB1 rs1045642 variant showed significant difference in PFS between patients with CC genotype and those with CT/TT genotypes (P = 0.020). In multivariate analysis, age (HR = 2.3; 95% CI, 1.2–4.2, P = 0.008), PS (HR = 2.4; 95% CI, 1.3–4.4, P = 0.007), and ABCB1 rs1045642 (HR = 1.9; 95% CI, 1.0–3.3, P = 0.036) were the independent risk factors for PFS. In our results, the most important prognostic factors associated with higher risk of progression were ABCB1 rs1045642 CC genotype, PS > 2, and older age.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

PCNSL:

primary central nervous system lymphoma

NHL:

non-Hodgkin lymphoma

DLBCL:

diffuse large B cell lymphomas

SNP:

single nucleotide polymorphism

OS:

overall survival

PFS:

progression-free survival

PS:

performance status

CSF:

cerebrospinal fluid

HD-MTX:

high-dose methotrexate

WBRT:

whole-brain radiotherapy

R:

rituximab

IDA:

idarubicin

Vm26:

teniposide

FDG-PET:

18F-2-fluoro-2-deoxy-d-glucose positron emission tomography

MRI:

magnetic resonance imaging

LDH:

lactate dehydrogenase

β2-MG:

β2-microglobulin

ALL:

acute lymphoblastic leukemia

References

  1. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-Oncology 14(Suppl 5):v1–v49. https://doi.org/10.1093/neuonc/nos218

    Article  PubMed  PubMed Central  Google Scholar 

  2. Camilleri-Broet S, Criniere E, Broet P, Delwail V, Mokhtari K, Moreau A, Kujas M, Raphael M, Iraqi W, Sautes-Fridman C, Colombat P, Hoang-Xuan K, Martin A (2006) A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107(1):190–196. https://doi.org/10.1182/blood-2005-03-1024

    Article  CAS  PubMed  Google Scholar 

  3. Carbone A, Gloghini A, Larocca LM, Capello D, Pierconti F, Canzonieri V, Tirelli U, Dalla-Favera R, Gaidano G (2001) Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 97(3):744–751

    Article  CAS  PubMed  Google Scholar 

  4. Kreher S, Johrens K, Strehlow F, Martus P, Borowiec K, Radke J, Heppner F, Roth P, Thiel E, Pietsch T, Weller M, Korfel A (2015) Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. Neuro-Oncology 17(7):1016–1021. https://doi.org/10.1093/neuonc/nov046

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell’Oro S, Zucca E, Cavalli F (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21(2):266–272

    Article  PubMed  Google Scholar 

  6. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24(36):5711–5715. https://doi.org/10.1200/jco.2006.08.2941

    Article  PubMed  Google Scholar 

  7. Roth P, Keller A, Hoheisel JD, Codo P, Bauer AS, Backes C, Leidinger P, Meese E, Thiel E, Korfel A, Weller M (2015) Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients. Eur J Cancer 51(3):382–390. https://doi.org/10.1016/j.ejca.2014.10.028

    Article  CAS  PubMed  Google Scholar 

  8. Mao X, Sun Y, Tang J (2014) Serum miR-21 is a diagnostic and prognostic marker of primary central nervous system lymphoma. Neurol Sci 35(2):233–238. https://doi.org/10.1007/s10072-013-1491-9

    Article  PubMed  Google Scholar 

  9. Kasenda B, Haug V, Schorb E, Fritsch K, Finke J, Mix M, Hader C, Weber WA, Illerhaus G, Meyer PT (2013) 18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma. J Nucl Med 54(2):184–191. https://doi.org/10.2967/jnumed.112.108654

    Article  CAS  PubMed  Google Scholar 

  10. Lee KM, Lan Q, Kricker A, Purdue MP, Grulich AE, Vajdic CM, Turner J, Whitby D, Kang D, Chanock S, Rothman N, Armstrong BK (2007) One-carbon metabolism gene polymorphisms and risk of non-Hodgkin lymphoma in Australia. Hum Genet 122(5):525–533. https://doi.org/10.1007/s00439-007-0431-2

    Article  CAS  PubMed  Google Scholar 

  11. Wang SS, Maurer MJ, Morton LM, Habermann TM, Davis S, Cozen W, Lynch CF, Severson RK, Rothman N, Chanock SJ, Hartge P, Cerhan JR (2009) Polymorphisms in DNA repair and one-carbon metabolism genes and overall survival in diffuse large B-cell lymphoma and follicular lymphoma. Leukemia 23(3):596–602. https://doi.org/10.1038/leu.2008.240

    Article  CAS  PubMed  Google Scholar 

  12. Al-Dayel F, Al-Rasheed M, Ibrahim M, Bu R, Bavi P, Abubaker J, Al-Jomah N, Mohamed GH, Moorji A, Uddin S, Siraj AK, Al-Kuraya K (2008) Polymorphisms of drug-metabolizing enzymes CYP1A1, GSTT and GSTP contribute to the development of diffuse large B-cell lymphoma risk in the Saudi Arabian population. Leuk Lymphoma 49(1):122–129. https://doi.org/10.1080/10428190701704605

    Article  CAS  PubMed  Google Scholar 

  13. Gra OA, Glotov AS, Nikitin EA, Glotov OS, Kuznetsova VE, Chudinov AV, Sudarikov AB, Nasedkina TV (2008) Polymorphisms in xenobiotic-metabolizing genes and the risk of chronic lymphocytic leukemia and non-Hodgkin’s lymphoma in adult Russian patients. Am J Hematol 83(4):279–287. https://doi.org/10.1002/ajh.21113

    Article  CAS  PubMed  Google Scholar 

  14. Morton LM, Schenk M, Hein DW, Davis S, Zahm SH, Cozen W, Cerhan JR, Hartge P, Welch R, Chanock SJ, Rothman N, Wang SS (2006) Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. Pharmacogenet Genomics 16(8):537–545. https://doi.org/10.1097/01.fpc.0000215071.59836.29

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Cerhan JR, Habermann TM, Maurer MJ, Wooldridge JE, Ansell SM, Nowakowski GS, Micallef IN, Thompson CA, Wang AH, Macon WR, Syrbu SI, Slager SL, Witzig TE, Link B (2010) Genetic polymorphisms in genes involved in R-CHOP metabolism and event-free and overall survival in diffuse large B-cell lymphoma. Blood 116(21):439–439

    Google Scholar 

  16. Chen BB, Xu XP, Shen L, Han TJ, Lin ZG, Chen Z, Kang H, Huang B, Lin GW (2013) Prognostic value of clinical characteristics and immunophenotypic biomarkers in 115 patients with primary central nervous system lymphoma. Chin Med J 126(3):482–487

    PubMed  Google Scholar 

  17. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science (New York, NY) 323(5922):1718–1722. https://doi.org/10.1126/science.1168750

    Article  CAS  Google Scholar 

  18. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM (2007) A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science (New York, NY) 315(5811):525–528. https://doi.org/10.1126/science.1135308

    Article  CAS  Google Scholar 

  19. Bogacz A, Mrozikiewicz PM, Deka-Pawlik D, Seremak-Mrozikiewicz A, Bartkowiak-Wieczorek J, Barlik M, Drews K, Kowalska A, Grzeskowiak E (2013) Frequency of G2677T/A and C3435T polymorphisms of MDR1 gene in preeclamptic women. Ginekol Pol 84(9):781–787

    Article  PubMed  Google Scholar 

  20. Vinolas N, Provencio M, Reguart N, Cardenal F, Alberola V, Sanchez-Torres JM, Baron FJ, Cobo M, Maestu I, Moreno I, Mesia C, Izquierdo A, Felip E, Lopez-Brea M, Marquez A, Sanchez-Ronco M, Taron M, Santarpia MC, Rosell R (2011) Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer (Amsterdam, Netherlands) 71(2):191–198. https://doi.org/10.1016/j.lungcan.2010.05.005

    Article  CAS  Google Scholar 

  21. Ma CX, Sun YH, Wang HY (2015) ABCB1 polymorphisms correlate with susceptibility to adult acute leukemia and response to high-dose methotrexate. Tumour Biol 36(10):7599–7606. https://doi.org/10.1007/s13277-015-3403-5

    Article  CAS  PubMed  Google Scholar 

  22. Li Y, Yan PW, Huang XE, Li CG (2011) MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev 12(9):2405–2409

    PubMed  Google Scholar 

  23. Wang Z, Wang T, Bian J (2013) Association between MDR1 C3435T polymorphism and risk of breast cancer. Gene 532(1):94–99. https://doi.org/10.1016/j.gene.2013.09.050

    Article  CAS  PubMed  Google Scholar 

  24. Ni Y, Yin G, Xiao Z, Fan L, Wang L, Wu Y, Wu H, Qian S, Xu W, Li J, Miao K, Qiu H (2016) MDR1 polymorphisms have an impact on the prognosis of Chinese diffuse large B cell lymphoma patients. Tumour Biol 37(1):1237–1244. https://doi.org/10.1007/s13277-015-3930-0

    Article  CAS  PubMed  Google Scholar 

  25. Gregers J, Green H, Christensen IJ, Dalhoff K, Schroeder H, Carlsen N, Rosthoej S, Lausen B, Schmiegelow K, Peterson C (2015) Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J 15(4):372–379. https://doi.org/10.1038/tpj.2014.81

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Yang YL, Lin DT, Chang SK, Lin SR, Lin SW, Chiou RJ, Yen CT, Lin KH, Jou ST, Lu MY, Chang HH, Chang WH, Lin KS, Hu CY (2010) Pharmacogenomic variations in treatment protocols for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 54(2):206–211. https://doi.org/10.1002/pbc.22292

    Article  PubMed  Google Scholar 

  27. Rao DN, Anuradha C, Vishnupriya S, Sailaja K, Surekha D, Raghunadharao D, Rajappa S (2010) Association of an MDR1 gene (C3435T) polymorphism with acute leukemia in India. Asian Pac J Cancer Prev 11(4):1063–1066

    PubMed  Google Scholar 

  28. Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, Bodalski J, Robak T (2004) Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 72(5):314–321. https://doi.org/10.1111/j.1600-0609.2004.00228.x

    Article  CAS  PubMed  Google Scholar 

  29. Kishi S, Cheng C, French D, Pei D, Das S, Cook EH, Hijiya N, Rizzari C, Rosner GL, Frudakis T, Pui CH, Evans WE, Relling MV (2007) Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 109(10):4151–4157. https://doi.org/10.1182/blood-2006-10-054528

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Suthandiram S, Gan GG, Zain SM, Bee PC, Lian LH, Chang KM, Ong TC, Mohamed Z (2014) Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics 15(11):1479–1494. https://doi.org/10.2217/pgs.14.97

    Article  CAS  PubMed  Google Scholar 

  31. Dervieux T, Greenstein N, Kremer J (2006) Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 54(10):3095–3103. https://doi.org/10.1002/art.22129

    Article  CAS  PubMed  Google Scholar 

  32. Organista-Nava J, Gomez-Gomez Y, Saavedra-Herrera MV, Rivera-Ramirez AB, Teran-Porcayo MA, Alarcon-Romero Ldel C, Illades-Aguiar B, Leyva-Vazquez MA (2010) Polymorphisms of the gamma-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico. Leuk Res 34(6):728–732. https://doi.org/10.1016/j.leukres.2009.11.027

    Article  CAS  PubMed  Google Scholar 

  33. Garcia-Bournissen F, Moghrabi A, Krajinovic M (2007) Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of gamma glutamyl hydrolase (GGH) gene. Leuk Res 31(7):1023–1025. https://doi.org/10.1016/j.leukres.2006.08.007

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This research was supported/funded by the Chinese Medicine Scientific Research Foundation of Shanghai Municipal Commission of Health and Family Planning (Grant No. 2014JP003A), the Science and Technology Development Fund of Bao Shan District (Grant No. 13-E-34), and the Shanghai Hospital Development Center (Grant No.16CR2043B).

Author information

Author notes

  1. Ting Wu, Hui Kang and Dongxiao Zhuang contributed equally to this work.

Authors and Affiliations

  1. Department of Hematology, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Urumqi Middle Road, Shanghai, 200040, China

    Ting Wu, Hui Kang, Yan Ma, Zhiguang Lin, Dina Suolitiken, Bobin Chen & Xiaoping Xu

  2. Department of Neurologic Surgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

    Dongxiao Zhuang

Authors
  1. Ting Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hui Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dongxiao Zhuang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yan Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhiguang Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dina Suolitiken
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bobin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiaoping Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Bobin Chen, Hui Kang, and Xiaoping Xu designed the research. Hui Kang, Dongxiao Zhuang, and Dina Suolitiken collected the clinical data. Ting Wu, Hui Kang, Yan Ma, and Zhiguang Lin performed the research. Ting Wu analyzed the data and wrote the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Bobin Chen or Xiaoping Xu.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Huashan Hospital. Written informed consent was obtained from the patients.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(PDF 366 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, T., Kang, H., Zhuang, D. et al. The role of ABCB1 polymorphism as a prognostic marker for primary central nervous system lymphoma. Ann Hematol 98, 923–930 (2019). https://doi.org/10.1007/s00277-019-03629-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-019-03629-7

Keywords

Search

Navigation